The people behind Evolvia.
A lean, capital-efficient team combining PHD/EGLN biology, precision-medicine, and industry-grade development experience.
Core team
Md Karim Ullah, PhD
PhD in Biochemistry & Molecular Medicine (Oulu); UChicago postdoc. Leads compound design and validation. Foundational PHD/EGLN biology (2017 Sci. Rep.).
Md Mizanur Rahman, PhD
Harvard University scientist; expertise in p53-mediated regulation and in vitro disease models — directly relevant to Evolvia's p53-priming mechanism.
Muhammad Rafiqul Islam, MD
Physician (MD); MS in Precision Medicine, University of Chicago. Leads external and scientific communications (remote).
Advisors
David Johnson, MBA
Advises on technical execution, translational infrastructure, and practical systems for outsourced development.
Emily Berghoff, PhD
Advises on industry-grade program assessment, drug-development strategy, and scientific prioritization.
Additional advisory
Advisory engagements being expanded as the program advances toward IND-enabling work.
How we work
Lean & capital-efficient
Outsourced synthesis (Enamine) and academic-core validation, with a parallel non-dilutive NIH SBIR track — capital flows into experiments, not fixed infrastructure.
Focused
One program: isoform-selective PHD1 inhibitors for MSS colorectal cancer. Key scientific and operational hires planned as funding advances.